High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy Aneuploidy is considered to play an important role in the pathogenesis of malignancies. We were interested whether abnormalities of the sister-chromatid separation regulator and proto-oncogene hSecurin occurred in myeloid leukaemias, and whether such abnormalities correlated with aneuploidy. The expression of hSecurin was assessed by real-time quantitative PCR in samples from patients with acute myeloid leukaemia (AML, n ¼ 70), chronic myeloid leukaemia (CML) in chronic phase (CP, n ¼ 20) or blast phase (BP, n ¼ 12), and granulocytes as well as mononuclear cells (MNCs) from healthy donors (n ¼ 21). Median hSecurin expression in AML with normal karyotypes was not significantly different from AML showing aneuploidy, CML BP or cells from healthy donors. However, hSecurin expression in CML CP was significantly increased compared to AML with normal karyotypes (1.82-fold; Po0.001), CML BP (3.18-fold; Po0.001), MNCs (3.17-fold; Po0.001) and granulocytes (2.69 fold; Po0.001) from healthy donors. Mutations in the coding region of hSecurin were not detected. These results do not support a major role of hSecurin in the development of aneuploidy in myeloid leukaemias. However, high expression of hSecurin may be of pathogenetic relevance in a subset of patients with regard to its potential to stimulate angiogenesis and to interact with the DNA-damage response pathway.
Introduction
It is widely appreciated that aneuploidy occurs in the majority of human cancers. 1 Numerical chromosome aberrations are also frequently observed in acute myeloid leukaemia (AML), and loss of chromosomes 5 or 7 has been repeatedly reported to confer an extremely poor outcome. [2] [3] [4] Recent studies suggest that other numerical chromosome abnormalities may also represent adverse prognostic factors. [4] [5] [6] In chronic myeloid leukaemia (CML), progression from Philadelphia chromosome positive but otherwise karyotypically stable chronic phase (CP) to blast phase (BP) is commonly accompanied by the occurrence of various numerical chromosome aberrations. 7 Although there is considerable debate as to whether aneuploidy constitutes an initial step in carcinogenesis or is the consequence of earlier molecular events affecting chromosomal stability, it is generally regarded as an important factor in the pathogenesis of malignant diseases. 8 Numerical chromosome aberrations are considered to result from defective segregation of sister chromatids during mitosis.
The highly conserved mitotic spindle checkpoint delays mitotic progression to anaphase in cells which either fail to align their replicated chromosomes on the metaphase plate or are unable to establish proper microtubule-kinetochore interaction. Once this is properly accomplished, the checkpoint allows for the activation of the anaphase-promoting complex/cyclosome (APC/ C), which promotes mitotic exit and re-entry into G1. 1 Another consequence of APC/C activation is the degradation of a protein called securin. Securin plays an essential role in the tightly controlled process of sister-chromatid separation by regulating separase, which cleaves the cohesin complex that binds chromatids together. [9] [10] [11] While intact, securin supports the nuclear accumulation of separase but inhibits its proteolytic activity. Upon degradation of securin at anaphase onset, separase becomes fully active and promotes the separation of chromatids. 11 The human securin is a protein of 202 amino acids that shows extensive sequence similarity with other vertebrate securins and contains a conserved motif that matches the destruction box (D-box) shared by many APC/C substrates. 12 It is encoded by a gene that is composed of five exons, localises to 5q33 and has been shown to be identical to human pituitarytumour-transforming gene 1. [12] [13] [14] The overexpression of this gene in mouse NIH 3T3 fibroblasts caused transformation in vitro and induced tumour formation in vivo when transfectants were injected into athymic nude mice. 13, 14 The expression of an undegradable securin mutant in NIH 3T3 cells led to incomplete chromatid separation, 15 and stable expression in the human osteosarcoma cell line MG-63 resulted in aneuploidy. 16 Human cells lacking hSecurin lose chromosomes at high frequency and demonstrate impaired cohesin cleavage and chromosome segregation. 17 High expression has already been reported for several solid human tumours, [18] [19] [20] but a possible association with the development of aneuploid karyotypes has not been investigated.
We were interested whether functional or structural abnormalities of the sister-chromatid separation regulator and protooncogene hSecurin occurred in myeloid leukaemias, and whether such abnormalities correlated with numerical chromosome aberrations. Therefore, we assessed hSecurin expression by real-time quantitative PCR and did sequence the analysis of the complete coding region in samples obtained from patients with AML or CML.
Materials and methods

Healthy donor and patient samples, cell lines
Freshly obtained peripheral blood (PB) from 21 healthy volunteers was diluted with the same volume of phosphatebuffered saline (PBS), carefully layered over Lymphoprep solution (Axis-Shield, Oslo, Norway) and centrifuged at 2500 r.p.m. for 20 min at room temperature. Mononuclear cells (MNCs) and granulocytes were collected separately from the corresponding interface, washed twice with PBS, and 600 ml of buffer RLT (Qiagen, Hilden, Germany) was added to approximately 1 Â 10 7 cells before storage at À701C. Patient samples (Table 1) were obtained at diagnosis and occasionally at relapse from individuals with AML (n ¼ 70) and CML in CP (n ¼ 20) or BP (n ¼ 12). Disease classification was carried out according to the recently published World Health Organisation (WHO) guidelines. 21 PB or bone marrow aspirates were processed immediately as described above to obtain MNCs, which were cryopreserved in pellets of 5 Â 10 7 cells in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 20% dimethyl sulphoxide (WAK-Chemie, Bad Soden, Germany) and 10% human albumin (Octapharma, Vienna, Austria) at À1921C. AML and CML BP samples contained at least 80% blasts as determined by Giemsa-MayFGrü newald-stained cytospin preparations.
Analysed cell lines were KG1 and HeLa, which were grown in standard conditions (available from the authors upon request) and cryopreserved at À1921C.
RNA isolation and cDNA preparation
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the RNeasy Mini Protocol for the isolation of total RNA from animal cells. RNA quantitation at 260 and 280 nm was performed using a Beckman DU 640 Spectrophotometer (Beckman, Fullerton, CA, USA), and samples were diluted to a concentration of 200 ng/ml total RNA. cDNA preparation was carried out from 2 mg of RNA using TaqMan Reverse Transcription Reagents (Applied Biosystems, manufactured by Roche, Branchburg, NJ, USA) according to the manufacturer's instructions, and cDNA was stored at À201C until further use.
Real-time quantitative PCR
Real-time quantitative PCR (RQ-PCR) was carried out using TaqMan methodology (Applied Biosystems, Foster City, CA, USA), which has been recently reviewed by Ginzinger. 22 Primers and probes were designed using the Primer Express software (Applied Biosystems) based on published GenBank sequences ( Table 2 ). To avoid amplification from contaminating genomic DNA, primers for hSecurin were selected to anneal to sequences in exons 3 and 4, which are separated by a 2.4 kb intron. We chose c-abl as the control gene since it had been recommended as a suitable control for quantitative RT-PCR of leukaemia-associated transcripts due to the lack of pseudogenes and its stable expression. 23 In addition, initial experiments demonstrated an expression level very similar to that of hSecurin, whereas the expression of b-2-microglobulin (b2-m) was significantly higher (data not shown). Primers and the probe for c-abl were designed in cooperation with Applied Biosystems (Table 2) . Amplifications were carried out in a volume of 25 ml using 5 ml of cDNA, 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems, manufactured by Roche, Branchburg, NJ, USA), 150 nM TaqMan probe and 300 nM forward and reverse primer. The reactions were carried out in the ABI Prism 7000 Sequence Detection System (Applied Biosystems) at standard conditions.
Relative quantitation was carried out using the comparative DDC T method according to the manufacturer's instructions (ABI Prism 7700 Sequence Detection System User Bulletin #2). The KG1 cell line was chosen as the calibrator because the expression of hSecurin observed in initial experiments was similar to leukaemic samples but lower than in HeLa cells, which are known to overexpress hSecurin.
14 All samples were analysed in triplicate and the median used for further calculations. The calibrator and HeLa cells as positive controls were included into each plate. Since the comparative DDC T method requires similar PCR efficiencies at or above 90% for the target and control gene, 22 and different efficiencies may be observed between patient and control samples, we first undertook a validation experiment: cDNA from randomly selected AML and healthy donor samples as well as from HeLa and KG1 cells was serially diluted over a concentration range of 1:1-1:1000, and the resulting C T values were plotted against the log 10 concentration. With a slope (S) between À3.4 and À3.6 for all experiments, the PCR efficiencies were 90-97% and thus satisfactory. 22 
PCR and sequencing
The entire coding region of the hSecurin gene was subjected to sequence analysis using three overlapping primer pairs (Table 2) . 
Karyotyping
Cytogenetic analyses of trypsin/Giemsa-banded bone marrow or PB preparations were performed according to standard procedures. The results were described according to the International System for Human Cytogenetic Nomenclature. 24 For the purpose of this analysis, samples were classified as aneuploid if they showed gain or loss of at least one complete chromosome.
Assessment of proliferation fraction
Immunohistochemical staining against Ki-67 for the assessment of proliferation fraction was carried out with the monoclonal antibody MIB-1 (Dako, Glostrup, Denmark) at a dilution of 1:100 on bone marrow biopsy specimens using cryostat sections. 25 Specimens were obtained on the same day as samples were used for expression and sequence analysis and karyotyping. Specific nuclear staining was measured by an experienced pathologist who was unaware of hSecurin expression at Â 40 objective magnification in at least 15 fields of view in each slide.
Statistics
Owing to the non-normal distribution of the expression analysis data, results are given as the median with the interquartile range (IQR). For comparison of hSecurin expression between sample groups, we used the Mann-Whitney U-test. The association between hSecurin expression and proliferation fraction was tested using Spearman's rank correlation. All tests were twosided and results considered significant if Po0.01. Calculations were carried out with SPSS 8.0 (SPSS Inc., Chicago, IL, USA).
Results
Cytogenetic analyses
Among the 46 of the 70 AML samples (66%) with successful karyotyping, 16 (35%) demonstrated aneuploidy and 10 showed gain or loss of more than one chromosome ( Table 3 ). The most frequent numerical chromosome aberrations were trisomy 8 (n ¼ 6), monosomy 7 (n ¼ 4), monosomy 17 (n ¼ 4) and monosomy 5 (n ¼ 3). In addition, five samples had a deletion involving 5q33. In all, 12 samples (26%) had only structural aberrations, while 18 (39%) were normal. For CML patients, cytogenetics were available in 29 of the 32 samples, which all harboured the classical t(9;22)(q34;q11). In the remaining three samples, diagnosis was confirmed by the presence of the BCR-ABL fusion transcript upon RT-PCR. None of the CP samples showed numerical chromosome aberrations, while three BP samples were aneuploid ( Table 3) .
Expression of hSecurin
The expression of hSecurin was quantified in all samples except one granulocyte sample from a healthy donor, which was excluded from further analysis due to low RNA yield (C T abl435). First, we aimed at comparing median hSecurin expression between disease categories with special regard to the presence of numerical chromosome aberrations, as well as in MNCs and granulocytes obtained from healthy donors. The group of AML without karyotypic abnormalities was chosen as our control group since MNCs or granulocytes from healthy We next intended to identify samples with abnormal hSecurin expression. Previous studies had suggested overexpression of hSecurin RNA and protein in HeLa cells, 14 which reached a relative expression level of 2.57 in our study. No expression 42.3 was observed in any of the samples from healthy donors we investigated. Therefore, this value was chosen as the cutoff for defining samples with 'high' hSecurin expression. Accordingly, five AML samples (7%) demonstrated high expression of hSecurin, which ranged from 2.97 to 15.67. One of these samples had multiple numerical and structural chromosome aberrations, two had only structural abnormalities and no cytogenetic results were available in the remaining 2. These five samples were AML with multilineage dysplasia (n ¼ 2) and AML not otherwise categorised (n ¼ 3). While high expression was not found in any of the BP samples, six CP samples (30%) showed high expression levels ranging from 2.33 to 7.57. Two AML samples had levels slightly below 0.11, which was the lowest expression observed in any of the MNCs or granulocytes. One of these samples showed numerous numerical and structural chromosome aberrations and was a therapy-related AML, while the other had a normal karyotype and was an AML not otherwise categorised. Among the eight patients with loss of a chromosome 5 or deletions involving 5q33, two had aberrant expression levels (0.07 and 14.32).
Sequence analysis
Direct sequencing of the entire coding region of hSecurin was carried out in 36 samples, which were selected because of high (n ¼ 6) or low (n ¼ 2) expression, presence of aneuploidy (n ¼ 15), loss of a chromosome 5 or deletions involving 5q33 (n ¼ 5), or because they were randomly chosen from the remaining samples (n ¼ 8). Aberrations from the normal sequence of hSecurin according to published studies and GenBank were not detected in any of the samples.
Assessment of proliferation fraction
Bone marrow biopsy specimens for MIB-1 staining to assess a potential association between proliferation rate and hSecurin expression were available from 25 AML and seven CML CP patients. Median MIB1 positivity was 50% (IQR 40-60%) for AML samples, which had a median hSecurin expression of 0.41, and 15% (IQR 10-20%) for CML CP samples, which had a median hSecurin expression of 1.32. There was an inverse correlation between MIB-1 positivity and hSecurin expression (r s ¼ À0.501, P ¼ 0.003).
Discussion
In AML, cytogenetic abnormalities are the most powerful predictor of response and long-term survival, [2] [3] [4] and therefore guide therapeutic decisions. The molecular consequences of certain chromosomal aberrations have in part been delineated, which has already resulted in improved treatment strategies for certain leukaemias such as acute promyelocytic leukaemia and CML. 27, 28 The cellular defects that cause structural or numerical chromosome aberration and might therefore become potential therapeutic targets as well are still undetermined. Owing to its function as a regulator of sister-chromatid separation, we reasoned that the proto-oncogene hSecurin might be implicated in the development of numerical chromosome aberrations in myeloid leukaemias. However, expression levels in blasts with aneuploid karyotypes did not differ from those with normal karyotypes or those with structural abnormalities. Furthermore, only one out of 19 leukaemic samples with numerical chromosome aberrations demonstrated high hSecurin expression. Moreover, we did not detect alterations of the coding sequence of hSecurin, which is of note since appropriate degradation of securin can be experimentally inhibited by mutations within the conserved D-box. 15 Neither mutations nor loss of expression were found in samples with only one hSecurin allele left due to loss or deletion of chromosome 5. These observations do not support a major role for hSecurin as a mediator of aneuploidy in myeloid leukaemias. Moreover, although our results cannot simply be applied to other types of human cancer, they challenge the significance of previous findings made in cell lines with experimentally induced hSecurin in myeloid leukaemias HW Auner et al overexpression or deletion of hSecurin. [15] [16] [17] In contrast to a report by Dominguez et al 26 on very low to absent expression of hSecurin in normal leucocytes and overexpression in the majority of haematopoietic neoplasms including AML, we found that hSecurin is stably expressed in both MNCs and granulocytes from healthy donors at a level that is not different from leukaemic myeloid blasts. These conflicting results may be explained by our use of the more sensitive RQ-PCR compared to Northern blotting in the report by Dominguez et al, who in addition studied only few individuals. The high hSecurin expression that we detected in a small number of AML samples was neither associated with specific cytogenetic aberrations nor with a particular WHO category, and leaves few speculative interpretations. Most notably, it has been reported that securin interacts with p53, which is mutated in approximately 15% of all AML cases, but in about one-fourth of therapy-related AML. 29, 30 One recent study found that securin inhibits the transcriptional activity of p53 and its ability to induce cell death, 31 while another claims that the overexpression of securin causes p53-dependent and -independent apoptosis and only leads to aneuploidy if p53 is deficient. 16 A third report shows that securin expression is inhibited by p53 after exposure to DNA-damaging agents. 32 Although these studies are in part conflicting, they strongly suggest a link between the pathways of sister-chromatid separation and DNA-damage response and justify further investigations of this topic in solid and haematopoietic malignancies. 33 Most researchers believe that numerical chromosome aberrations may be caused by alterations of genes or cellular structures which normally maintain the euploid karyotype. 1, 8 Potential candidates for the induction of aneuploidy other than hSecurin or the sister-chromatid separation pathway include members of the mitotic spindle checkpoint such as the BUB and MAD genes, which have been found to be mutated in some malignancies, albeit at a low frequency. [34] [35] [36] However, aneuploidy also occurs despite a functioning spindle checkpoint. 37 Hence, this may not be the major pathway leading to aberrant chromosome numbers. Interestingly, abnormalities of centrosomes were recently reported to correlate with numerical chromosome aberrations in AML, 38 and to occur together with chromosomal instability at very early stages of cancer development. 39 Gene expression studies in CML should always be interpreted with caution, particularly when comparisons between CP and BP are made, since haematopoietic cells at different stages of maturation are analysed. We found that hSecurin expression in CP was increased approximately three-fold not only compared to myeloid blasts but also to PB MNCs and granulocytes of healthy individuals. Since the expression of hSecurin is cellcycle regulated and high in cells that are actively growing but declining upon serum starvation, 40 we also correlated expression data with the proliferation rate as measured by MIB-1 staining against Ki-67. However, in the samples investigated, hSecurin expression was inversely correlated with MIB-1 positivity. This suggests that high expression levels in CML CP may be related to abnormal BCR-ABL signalling rather than reflect an increased proliferation rate. A possible pathogenetic relevance of the high expression of hSecurin in CP may evolve from observations that hPTTG stimulates basic fibroblast growth factor (bFGF) and induces angiogenesis, 14, 41 that high hPTTG expression has been associated with increased vascularisation in colorectal tumours 19 and that bFGF levels and vascularisation are higher in CML than in AML. 42 In conclusion, our studies demonstrate that high expression of the proto-oncogene and sister-chromatid separation regulator hSecurin occurs in the CP of CML and in some cases of AML, but neither expression nor sequence analyses support a major role in the development of aneuploidy. Owing to the multiple functions of hSecurin, which have just begun to be delineated, it nevertheless appears to be an attractive target for further investigations in different haematopoietic malignancies.
